Search Results - "Multiple sclerosis and related disorders"

The COVID-19 pandemic and the use of MS disease-modifying therapies by Giovannoni, Gavin, Hawkes, Chris, Lechner-Scott, Jeannette, Levy, Michael, Waubant, Emmanuelle, Gold, Julian

Get full text

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? by Novi, Giovanni, Mikulska, Malgorzata, Briano, Federica, Toscanini, Federica, Tazza, Francesco, Uccelli, Antonio, Inglese, Matilde

“…•A MS patient treated with ocrelizumab healed from COVID-19 without consequences•Immunosuppression might have played favorable role•This report supports the…”
Get full text

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran by Safavi, Farinaz, Nourbakhsh, Bardia, Azimi, Amir Reza

“…•4.8% of MS patients fulfilled defined criteria for COVID-19-suspect group.•Two patients required hospitalization; no intubation or ICU admission was…”
Get full text

Multiple sclerosis following SARS-CoV-2 infection by Palao, M., Fernández-Díaz, E., Gracia-Gil, J., Romero-Sánchez, C.M., Díaz-Maroto, I., Segura, T.

“…•The first case of multiple sclerosis (MS) shortly after COVID-19 is presented.•Viral infections strongly relate to MS onset and its relapses.•SARS-CoV-2 can…”
Get full text

Brain health: Time matters in multiple sclerosis by Giovannoni, Gavin, Butzkueven, Helmut, Dhib-Jalbut, Suhayl, Hobart, Jeremy, Kobelt, Gisela, Pepper, George, Sormani, Maria Pia, Thalheim, Christoph, Traboulsee, Anthony, Vollmer, Timothy

“…Abstract Introduction We present international consensus recommendations for improving diagnosis, management and treatment access in multiple sclerosis (MS)…”
Get full text

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients by Whittam, Daniel H, Cobo-Calvo, Alvaro, Lopez-Chiriboga, A Sebastian, Pardo, Santiago, Gornall, Matthew, Cicconi, Silvia, Brandt, Alexander, Berek, Klaus, Berger, Thomas, Jelcic, Ilijas, Gombolay, Grace, Oliveira, Luana Micheli, Callegaro, Dagoberto, Kaneko, Kimihiko, Misu, Tatsuro, Capobianco, Marco, Gibbons, Emily, Karthikeayan, Venkatraman, Brochet, Bruno, Audoin, Bertrand, Mathey, Guillaume, Laplaud, David, Thouvenot, Eric, Cohen, Mikaël, Tourbah, Ayman, Maillart, Elisabeth, Ciron, Jonathan, Deschamps, Romain, Biotti, Damien, Rostasy, Kevin, Neuteboom, Rinze, Hemingway, Cheryl, Forsyth, Rob, Matiello, Marcelo, Webb, Stewart, Hunt, David, Murray, Katy, Hacohen, Yael, Lim, Ming, Leite, M Isabel, Palace, Jacqueline, Solomon, Tom, Lutterotti, Andreas, Fujihara, Kazuo, Nakashima, Ichiro, Bennett, Jeffrey L, Pandit, Lekha, Chitnis, Tanuja, Weinshenker, Brian G, Wildemann, Brigitte, Sato, Douglas Kazutoshi, Kim, Su-Hyun, Huda, Saif, Kim, Ho Jin, Reindl, Markus, Levy, Michael, Jarius, Sven, Tenembaum, Silvia, Paul, Friedemann, Pittock, Sean, Marignier, Romain, Jacob, Anu

“…•Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children.•Rituximab reduced relapse rates in MOG-IgG-associated disorder…”
Get full text

MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder by Narayan, Ram, Simpson, Alexandra, Fritsche, Katelyn, Salama, Sara, Pardo, Santiago, Mealy, Maureen, Paul, Friedemann, Levy, Michael

“…•MOG antibody disease is the most recent antigen specific autoimmune disease on the NMO Spectrum.•MOG antibody disease is characterized by optic neuritis and…”
Get full text

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain by Montero-Escribano, Paloma, Matías-Guiu, Jorge, Gómez-Iglesias, Patricia, Porta-Etessam, Jesús, Pytel, Vanesa, Matias-Guiu, Jordi A.

Get full text

Effects of MS disease-modifying therapies on responses to vaccinations: A review by Ciotti, John Robert, Valtcheva, Manouela V., Cross, Anne Haney

“…: Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against…”
Get full text

How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms by Nikbakht, Farnaz, Mohammadkhanizadeh, Ali, Mohammadi, Ekram

“…•Seizure is one symptom of COVID-19.•Cytokine-storm in the brain is the most important reason of seizure in COVID-19•Pro-inflammatory cytokines cause neuronal…”
Get full text

Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment by Rejdak, Konrad, Grieb, Paweł

“…•We report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis, Parkinson's disease and…”
Get full text

Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States by Ehde, Dawn M., Roberts, Michelle K., Herring, Tracy E., Alschuler, Kevin N.

“…•As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS).•Two-thirds of the…”
Get full text

Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review by Shahmohammadi, Sareh, Doosti, Rozita, Shahmohammadi, Abootorab, Mohammadianinejad, Seyed Ehsan, Sahraian, Mohammad Ali, Azimi, Amir Reza, Harirchian, Mohammad Hossein, Asgari, Nasrin, Naser Moghadasi, Abdorreza

“…•Neuromyelitis Optica Spectrum Disorders is an autoimmune inflammatory demyelinating disease of the central nervous system.•There have been many reports on its…”
Get full text

The multiple sclerosis gut microbiota: A systematic review by Mirza, Ali, Forbes, Jessica D., Zhu, Feng, Bernstein, Charles N., Van Domselaar, Gary, Graham, Morag, Waubant, Emmanuelle, Tremlett, Helen

“…•No major differences in the overall gut microbiota composition in MS cases vs. controls.•Abundance of six taxa differed in MS cases vs. controls, similarly…”
Get full text

A case of possible atypical demyelinating event of the central nervous system following COVID-19 by Zoghi, Anahita, Ramezani, Mahtab, Roozbeh, Mehrdad, Darazam, Ilad Alavi, Sahraian, Mohammad Ali

“…•Clinical awareness of physicians about neurological complications of COVID-19 decreases the mortality rate among infected people.•Neurological presentation of…”
Get full text

Is it time to target no evident disease activity (NEDA) in multiple sclerosis? by Giovannoni, Gavin, Turner, Benjamin, Gnanapavan, Sharmilee, Offiah, Curtis, Schmierer, Klaus, Marta, Monica

“…Abstract The management of multiple sclerosis is becoming increasingly complex with the emergence of new and more effective disease-modifying therapies (DMT)…”
Get full text

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis by Baker, David, Pryce, Gareth, James, Louisa K., Marta, Monica, Schmierer, Klaus

“…•Ocrelizumab phase II trial extension data has 18-month post-drug follow-up.•Annualized relapse rate seems to remain low during the drug-free…”
Get full text

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis by Sahraian, Mohammad Ali, Azimi, Amirreza, Navardi, Samira, Ala, Sara, Naser Moghadasi, Abdorreza

“…•This study evaluates the incidence of COVID-19 in patients with MS, the rate of hospitalization or death in these patients.•The rate of hospitalization was…”
Get full text

Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life by Hanna, Mariam, Strober, Lauren Beth

“…•Depression and anxiety are both common in multiple sclerosis (MS).•Despite their high prevalence and comorbidity, greater attention has been given to…”
Get full text

The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? by Barin, Laura, Salmen, Anke, Disanto, Giulio, Babačić, Haris, Calabrese, Pasquale, Chan, Andrew, Kamm, Christian P., Kesselring, Jürg, Kuhle, Jens, Gobbi, Claudio, Pot, Caroline, Puhan, Milo A., von Wyl, Viktor

“…•Depending on the disease course, quality of life is affected by different symptoms.•For RRMS, gait and balance problems, and fatigue affect most quality of…”
Get full text